Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (1)
  • COX
    (1)
  • Endogenous Metabolite
    (1)
  • Interleukin
    (1)
  • NO Synthase
    (1)
  • Sirtuin
    (1)
  • Others
    (3)
TargetMol | Tags By ResearchField
  • Metabolism
    (2)
  • Nervous System
    (2)
  • Cancer
    (1)
  • Immune System
    (1)
  • Inflammation
    (1)
Filter
Search Result
Results for "

spt-in-1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    4
    TargetMol | All_Pathways
  • Isotope Products
    1
    TargetMol | Isotope_Products
SPT-IN-1
SPT Inhibitor 1, SPT Imidazopyridine 1
T288391933533-18-6
SPT-IN-1 (compound 1) is an orally active and highly potent inhibitor of serine palmitoyl transferase (SPT) with an IC50 value of 5.19 nM against human SPT1, SPT-IN-1 is utilized in metabolic disease research to explore sphingolipid biosynthesis regulation, insulin resistance mechanisms, and therapeutic strategies for type 2 diabetes and dyslipidemia.
  • $47
In Stock
Size
QTY
Nicotinamide-D4
Nicotinic acid amide-d4, Niacinamide-d4
T69395347841-88-7
Nicotinamide-D4 is a deuterium-labelled compound of Nicotinamide (TMSM-1731) for isotope tracing. Nicotinamide, a vitamin B3 derivative, inhibits SIRT1 and SIRT2.
  • $40
In Stock
Size
QTY
ARN 14494
T715541037837-27-6
ARN 14494 is a potent serine palmitoyltransferase inhibitor (SPT; IC50 = 27.3 nM). ARN 14494 inhibits synthesis of long chain ceramides and dihydroceramides in an in vitro model of Alzheimer's diease. The compound prevents the synthesis of proinflammatory cytokines and the oxidative stress-related enzymes iNOS and COX-2 in mouse primary cortical astrocytes. ARN 14494 is neuroprotective against β-amyloid 1-42 induced neurotoxicity in primary cortical neurons co-cultured with astrocytes.
  • $1,670
6-8 weeks
Size
QTY
SGF29-IN-1
T873836638-82-0
SGF29-IN-1 (Compound Cpd_DC60) serves as a selective inhibitor targeting the Tudor domain of the Spt-Ada-Gcn5 acetyltransferase (SAGA)-associated factor 29 (SGF29). It has demonstrated effectiveness in treating leukemia [1].
  • Inquiry Price
10-14 weeks
Size
QTY